The REMODEL study clarified which pathways are responsible for semaglutide’s cardiorenal effects in patients with CKD and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) are a ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback